No Prescription |
 |
 | ||
|
Seroflo Autohaler Advair |
|
| ||
No Prescription » Prescription Drugs 14 » Seroflo Autohaler Advair Seroflo Autohaler contains two medicines Salmeterol & Fluticasone.Salmeterol is a long acting bronchodilator. Bronchodilators help the airways in the lungs to stay open. This makes it easier for air to get in and out. The effects last for at least 12hours.Fluticasone is a corticosteroid which reduces swelling and irritation in the lungs.Seroflo helps to stop breathlessness and wheeziness coming on. It does not work once you are breathless or wheezy. If that happens you need to use a fast acting 'reliever' medication such as Salbutamol. Buy Seroflo Autohaler Advair and other Prescription Drugs 14 products online at Medstore. Buy Online at Medstore - Click Here!
About Seroflo Autohaler Advair: Product Type: Prescription Drugs 14 Seroflo Autohaler ( Advair Seretide Evohaler Generic Salmeterol & Fluticasone ) Seroflo Autohaler (Advair Seretide Evohaler Generic Salmeterol & Fluticasone) Advair Seretide Evohaler Generic Salmeterol & Fluticasone 25/125mcg 300MDI 25/125mcg 600MDI 25/125mcg 900MDI 25/250mcg 300MDI 25/250mcg 900MDI 25/250mcg 600MDI Advair Seretide Evohaler Generic Salmeterol & Fluticasone Seroflo Autohaler
View more Prescription Drugs 14 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
